KBY Biotech Indexv0.0.34
Search
← Pipeline|Tixazasiran

Tixazasiran

Phase 1
KTO-5018
By Kitov Pharma
Source: Trial-derived·Trials: 1
Modality
Degrader
MOA
RAS(ON)i
Target
MET
Pathway
Hedgehog
NASHMelanomaWet AMD
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
Aug 2021
→ May 2025
Phase 1Current
NCT04422835
1,759 pts·Melanoma
2021-08→2025-05·Active
1,759 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-1910mo agoInterim· Melanoma
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P1
Active
Catalysts
Interim
2025-05-19 · 10mo ago
Melanoma
Active|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT04422835Phase 1MelanomaActive1759PANSS
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
SNY-5783SanofiPhase 1/2METSTINGag
SotosacituzumabVertex PharmaPhase 1METTYK2i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
RVM-274Revolution MedicinesPhase 3METKIF18Ai
TalazasiranKymeraNDA/BLAMETCFTRmod